BioSpace News Archive

Omeros receives $125 million in gross proceeds in sale of a portion of projected royalties receivable on net sales of OMIDRIA.

Atsena Therapeutics announced positive results from the Phase I/II clinical trial of ATSN-101, its lead investigational gene therapy product formerly known as SAR439483, for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1).

Airway Therapeutics, Inc. (Airway), a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, announced the first patient dosed in Spain in its ongoing Phase 1b Trial of zelpultide alfa (rhSP-D) for preventative use in very preterm infants at risk for bronchopulmonary dysplasia (BPD).

Spero Therapeutics, Inc. today announced that it will host a virtual R&D event on Thursday, October 6, 2022, at 11:30 a.m. Eastern Time.

Centogene N.V., the commercial-stage essential biodata life science partner for rare and neurodegenerative diseases, announced reaching a significant milestone with the recruitment and genetic testing of 12,500 participants in the Rostock International Parkinson’s Disease Study.

Evommune, Inc. announced the appointment of Jeegar Patel, Ph.D., as Chief Scientific Officer.

OncoHost today announced two appointments to its executive team. Seasoned healthcare executive James “Jim” Whelan joins OncoHost’s board of directors and commercial oncology expert Chris Dingman joins as chief commercial officer.

Mirion Technologies, Inc. today announced the appointment of Michael Rossi as the President of Mirion Medical. Michael will report directly to Mirion’s CEO, Tom Logan, who had been acting as President of the business segment.

Recce Pharmaceuticals Ltd, the Company developing new classes of synthetic anti-infectives, is pleased to provide an updated timeline on its clinical programs with several significant data read-outs in 2022 and 2023.

Bausch Health Companies Inc. announced today, their endorsement of the implementation of K76.82, an ICD-10 code from the Centers for Medicare & Medicaid Services (CMS) for hepatic encephalopathy (HE), a complication of cirrhosis that affects the brain.